Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,506.48
(
-1.51%
)
US TECH 100
23,296.00
(
-1.79%
)
Dow Jones
45,577.47
(
-0.96%
)
Brent Oil
108.13
(
3.54%
)
Bitcoin
70,024.00
(
0.18%
)
News Focus
News Focus
Post# of 257263
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (3) Keep Next 10 Report Keyboard Shortcuts
Replies (3) Next 10 Prev Next

walldiver

Send PM Follow Ignore
Followers 24
Posts 1614
Boards Moderated 0
Alias Born 01/02/2003

walldiver

Re: DewDiligence post# 29477

Friday, 06/02/2006 1:31:22 PM

Friday, June 02, 2006 1:31:22 PM

Post# of 257263
I don't think DNA will even try to convince the docs to go quarterly. This is good news for OSIP and great news for REGN. Just picked up some more REGN on this news.

OSIP can try to position Macugen as the low-cost alternative, which IMO will only work with docs who worked with Eyetech on the clinical trials and/or won't try off-label Avastin.
Public Reply Private Reply New Post
Keep Last Read
Replies (3) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (3) Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today